Goodwin, Pamela J. http://orcid.org/0000-0003-2637-6906
Segal, Roanne J.
Vallis, Michael
Ligibel, Jennifer A.
Pond, Gregory R.
Robidoux, André
Findlay, Brian
Gralow, Julie R.
Mukherjee, Som D.
Levine, Mark
Pritchard, Kathleen I. http://orcid.org/0000-0003-0758-9666
Funding for this research was provided by:
Supported by Novartis Pharmaceuticals Inc. Canada and sponsored by the Ontario Clinical Oncology Group. Grant number not applicable.
Article History
Received: 8 October 2019
Accepted: 31 January 2020
First Online: 21 February 2020
Competing interests
: M.V. reports honoraria from Novo Nordisk, Merck, AbbVie, Bausch Health and Sanofi, and he is a consultant/advisor for Novo Nordisk, AbbVie, Bausch Health. G.P. reports that his spouse is employed and owns stock at Roche Canada. He is a consultant/advisor for Takeda DSMB. J.R.G. reports consultant/advisory activities for Roche/Genentech, Merck, Pfizer, Novartis, Puma, AstraZeneca, Sandoz/Hexal, Immunomedics, Genomic Health, Radius, InBiomotion. K.I.P. reports consultant/advisory activities for Pfizer, Roche, Amgen, Novartis, Eisai, Genomic Health Inc., Myriad Genetic Laboratories. All remaining authors have declared no conflicts of interest.